Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Br J Cancer ; 104(9): 1418-25, 2011 Apr 26.
Article in English | MEDLINE | ID: mdl-21468050

ABSTRACT

BACKGROUND: To date, no good marker for screening or disease monitoring of endometrial cancer (EC) is available. The aims of this study were to investigate HE4 gene, protein expression and serum HE4 (sHE4) levels in a panel of ECs and normal endometria (NEs) and to correlate sHE4 with patient clinicopathological characteristics and prognosis. METHODS: Using quantitative real-time PCR we tested 46 ECs and 20 NEs for HE4 gene expression. Protein expression was analysed by immunohistochemistry on tissue microarrays in 153 ECs and 33 NEs. Pre-operative serum samples from 138 EC and 76 NE patients were analysed with HE4-EIA assay. Association between sHE4 and patient clinicopathological characteristics or outcome was evaluated. RESULTS: Protein and HE4 gene were significantly upregulated in EC tissues and sera, compared with controls. High sHE4 levels were significantly associated with worse EC clinical characteristics. By univariate survival analysis, high sHE4 levels significantly correlated with decreased overall survival, progression-free survival and disease-free survival, retaining their independent prognostic value on the poorly differentiated EC cohort. CONCLUSION: We demonstrate, for the first time, that high sHE4 levels correlates with an aggressive EC phenotype and may constitute an independent prognostic factor for poorly differentiated-ECs. Determination of sHE4 could be clinically useful in identifying high-risk EC patients for a more aggressive adjuvant therapy.


Subject(s)
Biomarkers, Tumor/metabolism , Endometrial Neoplasms/blood , Endometrial Neoplasms/diagnosis , Endometrium/metabolism , Epididymal Secretory Proteins/metabolism , Adult , Aged , Analysis of Variance , Biomarkers, Tumor/blood , Biomarkers, Tumor/genetics , CA-125 Antigen/metabolism , Case-Control Studies , Diagnosis, Differential , Disease-Free Survival , Endometrial Neoplasms/metabolism , Endometrial Neoplasms/surgery , Enzyme-Linked Immunosorbent Assay , Epididymal Secretory Proteins/genetics , Epididymal Secretory Proteins/immunology , Female , Gene Expression Regulation, Neoplastic , Humans , Immunohistochemistry , Kaplan-Meier Estimate , Middle Aged , Polymerase Chain Reaction , Predictive Value of Tests , Preoperative Period , Prognosis , Protein Array Analysis , RNA, Messenger/metabolism , beta-Defensins
2.
Br J Cancer ; 99(5): 768-73, 2008 Sep 02.
Article in English | MEDLINE | ID: mdl-18682706

ABSTRACT

This study identifies the genetic fingerprint of poorly differentiated endometrioid endometrial carcinomas (G3-EEC) and analyses the potential utility of trefoil factor 3 (TFF3) as novel serum marker in G3-EEC. Affymetrix microarrays were used to identify the gene expression patterns of 19 snap-frozen G3-EEC and 15 normal endometrium (NE) biopsies. Quantitative real-time PCR (qRT-PCR) and immunohistochemistry were used to validate TFF3 expression. Finally, TFF3 serum levels were determined by ELISA in 25 G3-EEC patients, 42 healthy controls, and in 13 endometrial hyperplasia patients. Hierarchical cluster analysis showed TFF3 as the top differentially expressed gene between 363 upregulated genes in G3-EEC, when compared with NE. Trefoil factor 3 gene expression levels analysed by qRT-PCR significantly correlated with Affymetrix results (P<0.001; rs=0.85). By immunohistochemistry, TFF3 protein was significatively more expressed in EEC compared with NE (P<0.01), with cytoplasmatic positivity in 79% G3-EEC and 18% NE. Patients harbouring G3-EECs had significantly higher TFF3 serum concentration by ELISA when compared with healthy patients (P<0.001) or patients harbouring endometrial hyperplasia (P=0.012). In conclusion, TFF3 is highly expressed at gene and protein level in G3-EEC. Further investigations on a wider set of samples are warranted to validate TFF3 as a novel serum marker for early detection and/or monitoring of G3-EEC patients.


Subject(s)
Biomarkers, Tumor/blood , Endometrial Neoplasms/diagnosis , Gene Expression Profiling , Peptides/blood , Biomarkers, Tumor/genetics , CA-125 Antigen/blood , Cluster Analysis , Endometrial Neoplasms/blood , Endometrial Neoplasms/genetics , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunohistochemistry , Peptides/genetics , Trefoil Factor-3
3.
Int J Gynecol Cancer ; 18(1): 14-21, 2008.
Article in English | MEDLINE | ID: mdl-17451461

ABSTRACT

Uterine serous papillary carcinoma (USPC) is a rare and highly malignant form of endometrial cancer (EC) characterized by early metastasis, chemoresistance, and high mortality rate. Little is known about USPC tumorigenesis even if recently a HER-2/neu role has been suggested in its development and progression. The aim of the present study was to evaluate HER-2 expression by immunohistochemistry (IHC) in 12 USPC formalin-fixed, paraffin-embedded (FFPE) samples. Moreover, we looked at the correlation between HER-2 protein expression and HER-2/neu gene amplification by fluorescence in situ hybridization (FISH), other than HER-2/neu messenger RNA expression by quantitative real-time reverse transcription (RT)-polymerase chain reaction (PCR). Finally, these results have been compared with commonly evaluated clinical features in EC patients, in order to define the potential prognostic value of HER-2/neu overexpression in USPCs. A high expression of HER-2 protein by IHC was noted in 2 of 12 patients (16.6%), and the same cases showed specific HER-2/neu gene amplification by FISH. All the samples investigated displayed a perfect concordance between IHC and FISH data. Five (41.6%) of 12 tumors demonstrated polysomy of chromosome 17 and, focusing on the 2 USPCs that showed HER-2/neu overexpression, one of them (50%) was polysomic for chromosome 17. All the other USPC cases (58.4%) showed to be disomic for chromosome 17. Quantitative RT real-time PCR performed on complementary DNA obtained from all FFPE USPC samples showed a complete correlation with FISH and IHC data. Moreover, HER-2/neu overexpression was associated with a poorer overall survival and a very low relapse-free survival time, thus being considered a candidate marker of worse overall prognosis in USPC. The use of trastuzumab (Herceptin), a monoclonal antibody directed against HER-2/neu, for the therapy of patients with HER-2/neu-positive USPCs should be further investigated in clinical trials.


Subject(s)
Cystadenocarcinoma, Papillary/genetics , Gene Amplification , Receptor, ErbB-2/genetics , Receptor, ErbB-2/metabolism , Uterine Neoplasms/genetics , Uterine Neoplasms/metabolism , Aged , Aged, 80 and over , Cystadenocarcinoma, Papillary/metabolism , Cystadenocarcinoma, Papillary/pathology , Female , Humans , Immunoenzyme Techniques , In Situ Hybridization, Fluorescence , Lymph Nodes/pathology , Middle Aged , Neoplasm Invasiveness/pathology , Paraffin Embedding , Prognosis , Reverse Transcriptase Polymerase Chain Reaction , Survival Rate , Uterine Neoplasms/pathology
4.
Arch Virol ; 151(10): 1899-916, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16732494

ABSTRACT

Human papillomaviruses (HPVs), particularly HPV-16/18, are linked to cervical cancer development. Full-length, recombinant HPV-16/18 E7 oncoproteins were used in a new streptavidin-biotin capture ELISA method to investigate anti-HPV E7 antibody prevalence in serum. Sera from 99 healthy women, 70 cervical cancer patients, and 30 patients with cervical pre-invasive neoplasia were analyzed. Anti-HPV-16/18 E7 positivity was found in 53% of cervical cancer patients, in 40% with cervical pre-invasive neoplasia, and in 8% of healthy women. Serum samples from 12 cervical cancer patients were obtained at different time intervals during the treatment. Eleven out of 12 showed a correspondence between HPV-E7 antibody levels (decreasing versus increasing) and the type of response (clinically complete or partial response versus progression or stable disease) at each serological evaluation. Five patients with recurrent HPV-16/18-positive cervical carcinoma were analyzed before and after vaccination with HPV-16/18 E7-pulsed autologous dendritic cells; anti-HPV-16/18 E7 positivity was found in 3 out of 5 women. In conclusion, this assay could potentially be used as an adjunctive tool to monitor the type of response to treatment and possibly to detect antibody induction in cervical cancer patients after vaccination, as a potential marker to evaluate its efficacy.


Subject(s)
Antibodies, Viral/blood , Carcinoma/blood , Carcinoma/diagnosis , DNA-Binding Proteins/immunology , Enzyme-Linked Immunosorbent Assay/methods , Immunoglobulin G/blood , Oncogene Proteins, Viral/immunology , Precancerous Conditions/blood , Precancerous Conditions/diagnosis , Uterine Cervical Neoplasms/blood , Uterine Cervical Neoplasms/diagnosis , Antibody Specificity , Biomarkers/blood , Biotin , Cancer Vaccines/administration & dosage , DNA-Binding Proteins/biosynthesis , Disease Progression , Female , Humans , Immunoglobulin G/immunology , Oncogene Proteins, Viral/biosynthesis , Papillomavirus E7 Proteins , Papillomavirus Vaccines/administration & dosage , Recombinant Proteins/biosynthesis , Recombinant Proteins/immunology , Sensitivity and Specificity , Streptavidin , Vaccination
SELECTION OF CITATIONS
SEARCH DETAIL
...